The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
BRITISH JOURNAL OF HAEMATOLOGY(2016)
摘要
Older adult patients (60years) with acute myeloid leukaemia (AML) are generally considered to be poor-risk and there is limited information available regarding risk stratification based on molecular characterization in this age group, particularly for the double-mutant CEBPA (CEBPA(DM)) genotype. To investigate whether a molecular favourable-risk genotype can be identified, we investigated CEBPA, NPM1 and FLT3 status and prognostic impact in a cohort of 301 patients aged 60years or more with intermediate-risk cytogenetics, all treated intensively. Overall survival (OS) at 1year was highest in the 12 patients (4%) that were CEBPA(DM) compared to the 76 (28%) with a mutant NPM1 and wild-type FLT3 (NPM1(MUT)FLT3(WT)) genotype or all other patients (75%, 54%, 33% respectively), with median survival 152, 136 and 66months, although the benefit was short-term (OS at 3years 17%, 29%, 12% respectively). Combination of the CEBPA(DM) and NPM1(MUT)FLT3(WT) genotype patients defined a molecular group with favourable prognosis (P<00001 in multivariate analysis), with 57% of patients alive at 1year compared to 33% for all other patients. Knowledge of genotype in older cytogenetically intermediate-risk patients might influence therapy decisions.
更多查看译文
关键词
acute myeloid leukaemia,molecular prognostication,CEBPA genotype,NPM1 and FLT3 genotype
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要